Privi Speciality Chemicals Limited has received observation letters with 'no objection' from both BSE Limited and the National Stock Exchange of India Limited, marking a significant regulatory milestone in its proposed scheme of amalgamation. The BSE observation letter is dated May 06, 2026, while the NSE observation letter was dated May 05, 2026. Both disclosures were made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, on May 06, 2026. The observation letters are also being hosted on the company's website at https://privi.com/investor-relations/scheme-of-amalgamation-2025 .

Scheme of Amalgamation: Key Details

The proposed scheme involves the amalgamation of two transferor companies into Privi Speciality Chemicals Limited, which serves as the Transferee Company. The structure of the scheme is outlined below:

Background and Regulatory Progress

The Board of Directors of Privi Speciality Chemicals Limited had approved the proposed scheme of amalgamation between PSCL, PFSPL, and PBPL, along with their respective shareholders and creditors, as communicated through an earlier intimation dated December 19, 2025. The approval was granted subject to the receipt of requisite regulatory and statutory approvals. With observation letters now received from both NSE and BSE, the company has cleared two significant regulatory hurdles in the amalgamation process.

Pending Approvals

While both stock exchanges have issued their 'no objection' observation letters, the scheme remains subject to all other applicable regulatory and statutory approvals as required.

The intimation was signed by Ashwini Saumil Shah, Company Secretary and Compliance Officer of Privi Speciality Chemicals Limited, on May 06, 2026.

Privi Speciality Chemicals Limited has announced an earnings conference call scheduled for May 12, 2026, to discuss the operational and financial performance for the fourth quarter and financial year ended March 31, 2026. The announcement was made pursuant to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and communicated to both BSE Limited and National Stock Exchange of India Limited.

Earnings Conference Call Details

The earnings call will be held on Tuesday, May 12, 2026, at 4.00 p.m. IST. The company has requested participants to pre-register for the call through a designated link. A transcript of the conference call will be available on the company's website at www.privi.com within five working days post conclusion of the call.

Management Team Participation

The management team participating in the earnings call includes key executives from the company:

• Mr. Mahesh Babani – Chairman and Managing Director
• Mr. R. S. Rajan – President
• Mr. Narayan Iyer – Chief Financial Officer
• Mr. Sanjeev Patil – Executive Vice President, Strategy and Biotechnology
• Ms. Ashwini Shah – Company Secretary and Compliance Officer

Board Meeting Context

The earnings call follows a board meeting scheduled for May 11, 2026, at Privi House, A-71, TTC, Thane Belapur Road, Koparkhairne, Navi Mumbai, Maharashtra. The board will consider the approval of audited standalone and consolidated financial results under Ind-AS for the quarter and financial year ended March 31, 2026, and deliberate on the declaration of final dividend on equity shares.

Trading Window Status

The trading window for designated persons and their immediate relatives remains closed effective April 01, 2026, and is scheduled to reopen on Thursday, May 14, 2026, as part of the company's insider trading prevention measures. The communications were signed by Company Secretary Ashwini Saunil Shah.